Molecule intelOpportunity: Moderate0

Hydroxyprogesterone Caproate

8 brands · 4 companies · product forms

2 DRAP alerts

Opportunity snapshot

Launch attractiveness
37
Market saturation
11
Price room
6
Regulatory risk
70
8
brands
4
companies
Rs 254.84
median price
4
price points
1.23x
price spread
90
confidence %

Who competes here

Top companies by brand count — concentrated market · leader share 50%

Price room

Across observed sources and strengths
CheapestRs 228.26
MedianRs 254.84
Most expensiveRs 281.43
Spread1.23×
Sources: DRAP-official, Servaid

max/min price ratio 1.23x across 4 trusted points (Rs 228.26-281.43). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 2 live products for Hydroxyprogesterone Caproate — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2025-07-09
Suspension of marketing authorisations of 17-Hydroxyprogesterone caproate (17- OHPC) due t
Recall Alert: RECALL OF PRODUCTS CONTAINING HYDROXYPROGESTERONE CAPROATE

Why this score

Launch attractiveness

40% supply-gap(32) + 25% price-variation(6) + 20% low-competition(89) + 15% supply-disruption(40), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

4 canonical companies and 8 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 1.23x across 4 trusted points (Rs 228.26-281.43). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

2 DRAP alert(s), latest 2025-07-09 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.